Journal of Clinical Oncology
Articles in this Issue
Design of an innovative clinical development program using randomized controlled phase 2 trial data and real-world evidence from an expanded access protocol to assess mifomelatide (TCMCB07) in GI cancer cachexia.
TPS11200 Background: Cachexia is common in GI cancers, occurring in ~50% of patients with colorectal cancer (CRC) and up t...
Clinical benefits of early-phase clinical trials for rare malignancies: Asian single-center analysis.
e15202 Background: The available chemotherapies for patients with rare malignancies are limited. Enrollment in early-phase...
Opportunistic plasma ctDNAtesting in EGFR-mutant mNSCLC using a hospital-validated sequencing platform: A real-world experience.
e20564 Background: In metastatic EGFR-mutant non-small cell lung cancer (mNSCLC), rapid identification of targetable alter...
Predictors of meaning and purpose among patients with cancer and with elevated psychological distress.
e24123 Background: Patients with cancer frequently experience psychological distress and existential concerns. Meaning and...
Collaborative education to advance equitable prostate cancer care in geographically diverse communities.
9033 Background: Although 15%-19% of the US population resides in rural areas, less than 10% of oncologists practice there...
Impact of UGT1A1 polymorphism on safety and dose management of sacituzumab govitecan in the treatment of advanced breast cancer patients.
e15143 Background: Sacituzumab govitecan (SG) is an antibody-drug conjugate approved for advanced triple-negative and HR+/...
Evaluating satisfactory testing versus transcript grade performance between childhood cancer survivors and healthy controls.
10045 Background: Substantial evidence suggests that survivors of childhood cancer are at increased risk for poor academic...
Phase II trial evaluating nivolumab in patients with recurrent IDH-mutant gliomas with and without hypermutation phenotype.
2064 Background: Tumor mutational burden (TMB) is an emerging biomarker for the prediction of immune therapy success in so...
Metabolic and inflammatory marker elevations and associations with hormone therapy usage in prostate cancer patients of the All of Us Research Program cohort.
5031 Background: The development of cardiovascular disease (CVD) involves an interplay of inflammatory and metabolic facto...
Interpretable machine learning for overall survival prediction in vulvar cancer: SEER-based development and external validation in a Chinese multicenter cohort.
e17651 Background: Vulvar cancer is a rare gynecologic malignancy, and accurate prognostic tools for avoiding under- or ov...
First-in-human trial of BH-30643, a novel macrocyclic, non-covalent, mutant-selective OMNI-EGFR inhibitor, in <i>EGFR</i> -mutant ( <i>EGFR</i> m) NSCLC.
3014 Background: Macrocyclic next-generation tyrosine kinase inhibitors (TKIs) have transformed outcomes in ALK- and ROS1-...
Mammography utilization and male breast cancer in BRCA1/2 carriers.
10563 Background: Males with pathogenic germline variants in BRCA1 /2 (BRCA+) have...
Demographic and clinical patterns of basosquamous carcinoma: An NCDB analysis.
e21548 Background: Basosquamous carcinoma (BSC) is a rare cutaneous malignancy with histopathologic features of both basal...
Malnutrition as associated with high-risk airway failure phenotypes in hospitalized head and neck cancer: A national, site-specific analysis.
e23172 Background: Malnutrition is common in patients with head and neck cancer (HNC) and is associated with adverse outco...
The influence of COVID-19 severity on the local lung hormonal profile in patients with non-small cell lung cancer.
e20047 Background: Lung cancer is a leading cause of cancer-related mortality, with pronounced sex differences. The COVID-...
The role of NECTIN4 in shaping the tumor microenvironment and potentiating the efficacy of immunotherapy in bladder cancer.
4574 Background: The EV-302 trial established enfortumab vedotin plus pembrolizumab (EV/P) as first-line therapy for metas...
Cardiotoxicity diagnoses and inpatient outcomes in principal breast cancer hospitalizations: National Inpatient Sample, 2018–2023.
e24036 Background: Cardiotoxicity diagnoses are increasingly recognized among patients with cancer, yet national data desc...
Evidence-linked complementary care AI supporting standard oncology: Real-world outcomes in pancreatic, HNSCC, and prostate cancer.
e23381 Background: Complementary care may improve oncology treatment tolerance but often lacks rigorous safeguards. We dev...
Network meta-analysis of first-line therapies for unresectable HER2-negative gastric/gastroesophageal junction adenocarcinoma: Efficacy and safety of novel combinations versus standard chemoimmunotherapy.
e16045 Background: For patients with unresectable HER2-negative advanced gastric or gastroesophageal junction adenocarcino...
Stomatitis as a harbinger of harm: Long-term mortality and multiorgan adverse events associated with immune-related stomatitis in checkpoint inhibitor-treated melanoma—A propensity score–matched cohort study.
e21600 Background: Immune checkpoint inhibitors (ICIs) have revolutionized treatment for advanced malignant melanoma, but...
Impact of prophylactic cyclophosphamide on ALC and delayed neurotoxicity after cilta-cel.
7543 Background: Delayed neurotoxicity (DNT) after ciltacabtagene autoleucel (cilta-cel) is associated with severe morbidi...
Analysis of circulating small extracellular vesicle-associated miRNA in head and neck squamous cell carcinoma (HNSCC): Biomarker discovery in pre-operative neoadjuvant nivolumab.
2577 Background: Standard treatment options for HNSCC include chemotherapy, radiation, surgery, and immunotherapy. Immune...
Population-based prediction of cardiovascular mortality in gynecologic cancer survivors using machine learning (RISKHEART).
5518 Background: General-population cardiovascular disease (CVD) risk scores underperform in cancer survivors by failing t...
Prediction of progression in MGUS using transformer-based survival time-series modeling.
7518 Background: Monoclonal gammopathy of undetermined significance (MGUS) is common, yet only a minority progress to mali...
Real-world outcomes and circulating tumor DNA (ctDNA) dynamics in patients (pts) with microsatellite instability–high (MSI-H) metastatic colorectal cancer (CRC) treated with immune checkpoint inhibitors (ICI).
3516 Background: ICIs produce durable benefit in MSI-H CRC, yet optimal treatment duration and monitoring strategies remai...